secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptimizeRx Corp (OPRX)
CIK:        0001448431
Form:       8-K
Filed at:   2024-04-18T23:59:59+00:00
Accession:  0001213900-24-034128
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OptimizeRx Q4 revenue $28.4M (+44% YoY), non-GAAP net income $4.6M, reiterates 2024 guidance of $100M revenue
--------------------------------------------------------------------------------

- Q4 revenue $28.4M (+44% YoY); gross profit $17.8M (63% margin).
- GAAP net loss $4.1M ($0.23/share); non-GAAP net income $4.6M ($0.26/share).
- Full year revenue $71.5M (+15%); GAAP net loss $17.6M; non-GAAP net income $4.4M.
- Adjusted EBITDA Q4 $5.8M (+50% YoY); full year $3.6M.
- Reiterates FY2024 guidance: revenue ≥$100M, Adjusted EBITDA ≥$11M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1448431/000121390024034128/0001213900-24-034128-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1448431/000121390024034128/ea0204128-8k_optimizerx.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-034128

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer